MEMORANDUM

SUBJECT: Parathion, 90-day Neurotoxicity Study in Rats

TO: Joshua First PM 61
Reregistration Branch
Special Review and Reregistration Division (7508C)

FROM: Robert F. Zenózian Ph.D.
Senior Pharmacologist
Toxicology Branch I
Health Effects Division (7509C)

THROUGH: Karl Baetcke Ph.D.
Chief
Toxicology Branch I
Health Effects Division (7509C)

Compound: Parathion
Registration #: 057501
MRID 434915-01

Action Requested
Review the following study:

Citation
Subchronic neurotoxicity study of dietary parathion in rats.

Study Type Subchronic neurotoxicity, Guideline 82-7

Core Classification Acceptable

Conclusions
Rats dosed at 0, 1, 50 and 100 ppm males and 0, 1, 25 and 50 ppm females for 13 weeks. Control and high dose recovery
animals carried on basal diet for an additional 4 weeks. Body weight gain decreased in both sexes at high dose. Erythrocyte cholinesterase activity decreased significantly in males and hippocampus females. LOEL 1 ppm (LDT). Blood and brain all areas cholinesterase activity decreased significantly at 50 ppm males and 25 ppm females. Only plasma and cerebellum activity recovered at the high dose in both sexes at 17 weeks. Neurotoxicity, pupillary response LOEL 50 ppm males 25 ppm females, NOEL 1 ppm both sexes. Forelimb grip strength, LOEL 50 ppm females, NOEL 25 ppm. Hindlimb grip strength, LOEL 100 ppm males 50 ppm females, NOELs 50 ppm males, 25 ppm females.

Discussion

Dose related depression of cholinesterase activity was clearly the most sensitive indication of parathion toxicity in this study showing significant depression at the respective mid and high doses for both sexes with minimal recovery. Dose related and statistically significant depression of cholinesterase activity in plasma, erythrocytes and all brain sections in both sexes at their respective intermediate and high doses (males 50 and 100 ppm and females 25 and 50 ppm). In the 1 ppm males erythrocyte cholinesterase activity was statistically significantly depressed at 8 and 14 weeks, 86 and 85 percent of controls respectively. In the 1 ppm females hippocampus activity was statistically significantly depressed 14 weeks (78 percent of control). In the high dose recovery animals at 17 weeks, plasma and cerebellum cholinesterase activity had recovered. Erythrocyte and the remaining brain area activity had recovered to some extent but the remaining depression was statistically significant.

Body weight and weight gains were depressed in the respective high doses in males and females.

Very few of the parameters in the functional observational battery gave any indication of a treatment related effect. The only clearly observed effects were fore and hindlimb grip strength at the respective high doses in both sexes.

At 8 weeks one high dose female (50 ppm) and 2 high dose males (100 ppm) showed tremors. At 13 weeks one mid dose (25 ppm) and one high dose female (50 ppm) showed tremors. At 8 and 13 weeks there were 'subjective' observations of slow and/or partial pupillary constriction in intermediate and high dose animals in both sexes. The number of animals showing the effect appeared to be dose related.

Forelimb grip strength showed a statistically significant decrease (p<0.5) in the high dose females (50 ppm) at 4, 8 and 13 weeks. A dose-response relationship not apparent in the lower doses.
Hindlimb grip strength showed a statistically significant decrease (p < 0.5) in the high dose females (50 ppm) at 4, 8 and 13 weeks. A dose-response relationship not apparent in the lower doses. Statistically significant decrease (p < 0.5) in the high dose males (100 ppm) at 4 and 13 weeks. A dose-response relationship not apparent in the lower doses.
Compound: Parathion

Study Type: Subchronic neurotoxicity, Guideline 82-7

Citation:
Subchronic neurotoxicity study of dietary parathion in rats.

Reviewed by Robert F. Zendzian PhD
Senior Pharmacologist

Core Classification: Acceptable

Conclusions:
Rats dosed at 0, 1, 50 and 100 ppm males and 0, 1, 25 and 50 ppm females for 13 weeks. Control and high dose recovery animals carried on basal diet for an additional 4 weeks. Body weight gain decreased in both sexes at high dose. Erythrocyte cholinesterase activity decreased significantly in males and hypcampus females, LOEL 1 ppm (LDT). Blood and brain all areas cholinesterase activity decreased significantly at 50 ppm males and 25 ppm females. Only plasma and cerebellum activity recovered at the high dose in both sexes at 17 weeks. Neurotoxicity, pupillary response LOEL 50 ppm males 25 ppm females, NOEL 1 ppm both sexes. Forelimb grip strength, LOEL 50 ppm females, NOEL 25 ppm. Hindlimb grip strength, LOEL 100 ppm males 50 ppm females, NOELs 50 ppm males, 25 ppm females.

Materials:
Ethyl parathion (parathion)
Technical
Batch 70813-01
brown liquid
purity 96.2%
from Cheminova Agro A/S May 3, 1993

Vehicle
Agway® Prolab® Certified rodent feed (RMH 3200 Meal)

Sprague-Dawley Crl:CD®BR rats
4-week old males and females
(7 weeks when placed on study)
From Charles River Laboratories
Raleigh NC,
Nov 30, 1993
Experimental design

<table>
<thead>
<tr>
<th>Group</th>
<th>Pose level ppm</th>
<th>Number of Animals</th>
<th>Neurotox Male</th>
<th>Neurotox Female</th>
<th>Cholinesterase Male</th>
<th>Cholinesterase Female</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Male</td>
<td>Female</td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td>1</td>
<td>0</td>
<td>10\textsuperscript{a}</td>
<td>10\textsuperscript{a}</td>
<td>-</td>
<td>5\textsuperscript{b}</td>
<td>5\textsuperscript{b}</td>
</tr>
<tr>
<td>control</td>
<td></td>
<td>-</td>
<td>-</td>
<td>5\textsuperscript{c}</td>
<td>5\textsuperscript{c}</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td>10\textsuperscript{a}</td>
<td>10\textsuperscript{a}</td>
<td>-</td>
<td>5\textsuperscript{b}</td>
<td>5\textsuperscript{b}</td>
</tr>
<tr>
<td>low</td>
<td></td>
<td>-</td>
<td>-</td>
<td>10\textsuperscript{a}</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>25</td>
<td>-</td>
<td>-</td>
<td>10\textsuperscript{a}</td>
<td>-</td>
<td>5\textsuperscript{b}</td>
</tr>
<tr>
<td>mid-low</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>50</td>
<td>10\textsuperscript{a}</td>
<td>10\textsuperscript{a}</td>
<td>-</td>
<td>5\textsuperscript{b}</td>
<td>5\textsuperscript{b}</td>
</tr>
<tr>
<td>mid-high</td>
<td></td>
<td>-</td>
<td>-</td>
<td>5\textsuperscript{d}</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>5</td>
<td>100</td>
<td>10\textsuperscript{a}</td>
<td>-</td>
<td>-</td>
<td>5\textsuperscript{b}</td>
<td>-</td>
</tr>
<tr>
<td>high</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5\textsuperscript{d}</td>
<td>-</td>
</tr>
</tbody>
</table>

a. neurotox animals
b. cholinesterase animals
c. recovery cholinesterase animals
d. recovery behavior animals

Dose preparation

Dietary mixes were prepared weekly. No adjustment made for purity of technical material. Group 5 mix was used as stock for group five mix. Groups 3-5 mixes were prepared individually. Fresh diets were presented weekly and were available 7 days/week for at least 13 weeks until the day before necropsy. The recovery animals were returned to basal diet after at least 13 weeks on treated diet and maintained until sacrifice during week 17.

Homogeneity and stability analysis were performed on the 1, 25, and 100 ppm dose concentrations. Duplicate samples of each concentration (including control) from weeks 1, 4, 8 and 14 were analyzed for concentration of test material. Samples of each dietary formulation were stored frozen for possible additional analysis.

Observations

Rats were observed twice daily for morbidity and mortality. A thorough clinical analysis was performed at each weighing.

BEST COPY AVAILABLE
Rats were weighed before treatment and weekly thereafter. Food consumption was measured weekly.

"An indirect ophthalmoscopic examination was performed on each rat prior to treatment and on the neurotox control, mid-high-dose female and high-dose male rats prior to termination (week 14) using 1% Hydriacyl® as the mydriatic agent."

**Cholinesterase determinations**

Blood samples were taken from the cholinesterase animals before dosing and at weeks 4, 8, and 13 for plasma and RBC cholinesterase determination. Blood samples were taken from the recovery cholinesterase animals at week 17 for plasma and RBC cholinesterase determination. Brain samples were collected from all cholinesterase animals at termination (13 and 17 weeks respectively). Blood samples were collected from the orbital sinus, during the last three hours of the animals light cycle under CO₂/O₂ anesthesia.

Shortly after collection of the terminal blood samples, cholinesterase animals were anesthetized with CO₂/O₂ and decapitated. The brains, including the olfactory lobes were removed and six regions (olfactory bulbs, cerebelum, cortex, striatum, hippocampus and midbrain plus brainstem) were isolated (based on a modification of the method of Glowinski & Iverson 1) for individual cholinesterase determination.

Cholinesterase analysis were performed on the BMD/Hitachi® 704 Chemistry Analyser.

**Neurobehavioral Assessment**

The Functional Observational Battery (FOB) was conducted on 10 animals prior to dosing and at weeks 4, 8, and 13. In addition the pupil response test was performed on the recovery animals during weeks 13 and 16. Testing was performed blind during the dark cycle at approximately the same time of day for each interval. With the exception of the performance measures all neurobehavioral assessments were performed under red-light and white-noise conditions.

**Observations**

"As each animal was removed from its cage, the following parameters were evaluated:

- appearance of fur
- color of tears/deposits around eyes
- convulsions/tremors
- lacrimation
- other signs
- palpebral closure

ease of handling/body tone  piloerection
ease of removal from cage  respiration
excessive vocalizations  salivation
exophthalmus  writhing"

"After home cage observations, each animal was placed into a Plexiglas arena (66L X 48W X 30.5 H cm) on a flat surface covered with a clean absorbent paper for a 1-minute period to evaluate the following parameters:

arousal  other signs
circling  posture
covulsions  stereotypy
gait  tremors"

"The following responses were evaluated in the testing arena at the end of the 1-minute period:
ligh approach response  pupil response
cataplexy  righting reflex
olfactory response  touch reflex
other signs"

"The following parameters were evaluated at the same intervals as the POB testing:

forelimb grip strength  rectal body temperature
hindlimb grip strength  tail flick latency
landing foot splay"

Criterial for neurolotoxicological findings are presented in Appendix I of this DER (pages 26 and 27 of the report).

"Automated Auditory Startle Response -The auditory startle response was measured by placing each animal in a sound-attenuated automated audiory startle chamber which measures the muscular force (i.e. the force generated by motor movement or "startle") that occurs in response to the presentation of an auditory stimulus (i.e. tone). The parameters measured and reported for both the prestimulus (control habituation period, no tone) and stimulus (tone) trials included the maximum input voltage [mv] (MXI, the time to reach maximum response), the maximum input time [msec], (MXIT, the time to reach maximum amplitude of the muscular response following the presentation of the auditory stimulus) and the average input voltage [mv], (AVI, the average amplitude of the muscular response over a 100-msec recording window). The auditory startle equipment was calibrated prior to each interval by using a standard stimuli in each chamber. Animals were assigned
to placement in the devices by rotating through the groups to ensure that the treatment groups were balanced across the separate chambers.

"Locomotor Activity - Locomotor activity was monitored prior to initiation of treatment and at weeks 4, 8 and 13. Each animal was placed in an automated photocell activity monitoring device (San Diego Instruments, Model PAS) for a period of 40 minutes. The movement of each animal was recorded as activity counts (photo beam breaks) in 1-minute intervals. The motor activity equipment was calibrated and the diagnostics program run prior to each interval to ensure that all photobeams and receptors functioned properly. The locomotor activity counts were converted into eight blocks of 5 minutes each for statistical analysis and tabular presentation. Animals were placed in the devices by rotating through the groups to ensure that the treatment groups were balanced across the separate chambers."

Termination

"On the day of scheduled necropsy (week 14), following an overnight fast, all neurotox animals were weighed and given an intraperitoneal injection of sodium pentobarbital. Preceding gross necropsy, a whole body perfusion was performed on six (first six successful perfusions) rats/sex/group. Heparinized saline was perfused through the left ventricle, followed immediately by buffered glutaraldehyde-paraformaldehyde solution. All remaining neurotox rats in each group were esanguinated and a gross necropsy was conducted on each animal. Designated recovery behavioral animals (controls, high dose males and mid-high dose females) were sacrificed via CO2/O2 inhalation and esanguination during week 17 without a gross necropsy. Necropsies included examination of the following:

all orifices
external surface of the brain
(at necropsy)

carcass
nasal cavity and paranasal sinuses
cervical tissues and organs
thoracic, abdominal and pelvic
cranial cavity
cavities and their viscera"

"The following tissues (when present) from each perfused animal were collected and preserved in 10% neutral-buffered formalin:

Anterion tibialis muscles
lumbar dorssal and ventral root
brain with brainstem (medulla/pons
fibers
cerebellar cortex and cerebral
lumbar spinal cord
cortex)
lumbar dorsal root ganglia
cervical dorsal root and ventral root fibers  macroscopic lesions
cervical spinal cord    mid-thoracic spinal cord
pars dorsal root ganglia  pituitary
eyes with portion of optic nerve  sciatic nerve
gasserian ganglion   sural nerve
gastrocnemius muscles  tibial nerve

Macroscopic lesions in nonperfused animals were saved.

Histopathology

"The proximal sciatic, sural and tibial nerves from the perfused animals in Group 1, Group 4 females and Group 5 males were embedded in both plastic (glycol methacrylate) and paraffin and examined microscopically. For cross sections, the tissues embedded in plastic were sectioned at approximately 1 u, mounted and stained with cresyl fast violet. For longitudinal sections, the tissues embedded in paraffin were sectioned at approximately 5 u, mounted and stained with luxol fast blue and counter stained with periodic acid-Schiff."

"All other preserved tissues from the perfused animals in Group 1, Group 4 females and Group 5 males were imbedded in paraffin, sectioned at 5 u, mounted and stained with hemotoxylin and eosin and examined microscopically."

Statistical Analysis

"Body weight, body weight change, food consumption and cholinesterase data of the control group were compared statistically with the data from the same sex of the treated groups." An outline of the statistical procedure is presented in Figure 1 from the report (Appendix II).

Results

Analysis of the diet showed that homogeneity, stability and concentration were within 10% of target doses.

No morbidity or mortality was observed in the study.
No evidence of treatment related toxicity was observed clinically.

Ophthalmoscopic examination reported that the eyes of control and high dose treated animals showed no differences that could be attributed to treatment. However individual observations were not reported.
Body weights and weight gain was depressed at the high dose in the males (100 ppm) and the females (50 ppm). Food intake appeared depressed in the males at the high dose but not in the females.

Cholinesterase activity is summarized in Text Table 1 from the report (Appendix II, page 46). Statistically significant decreases in activity (related to controls) were seen at 50 and 100 ppm in all parameters (blood and brain) tested in the males. Similar results were observed in the females at 25 and 50 ppm except in the cerebellum where a 71% of control, value was not statistically significant.

Cholinesterase activity at 1 ppm in both sexes showed a three values significantly depressed and two other values depressed is an extent that is suspicious but not statistically significant. For these latter parameters individual animal values were examined.

In males at 1 ppm erythrocyte cholinesterase was significantly depressed at 8 and 14 weeks. Terminal cerebellum cholinesterase activity was 61% of control at week 14 but the difference was not statistically significant. Individual animal values were as follows:

<table>
<thead>
<tr>
<th></th>
<th>0 ppm</th>
<th>1 ppm</th>
<th>50 ppm</th>
<th>100 ppm</th>
</tr>
</thead>
<tbody>
<tr>
<td>#</td>
<td>U/L</td>
<td>U/L</td>
<td>U/L</td>
<td>U/L</td>
</tr>
<tr>
<td>B43792</td>
<td>1660</td>
<td>1600</td>
<td>960</td>
<td>520</td>
</tr>
<tr>
<td>B43793</td>
<td>9480</td>
<td>2480</td>
<td>620</td>
<td>680</td>
</tr>
<tr>
<td>B43794</td>
<td>1880</td>
<td>2100</td>
<td>880</td>
<td>740</td>
</tr>
<tr>
<td>B43795</td>
<td>2380</td>
<td>2220</td>
<td>900</td>
<td>860</td>
</tr>
<tr>
<td>B43796</td>
<td>2920</td>
<td>2720</td>
<td>1020</td>
<td>640</td>
</tr>
<tr>
<td>mean</td>
<td>3664</td>
<td>2224</td>
<td>876</td>
<td>688</td>
</tr>
<tr>
<td>percent</td>
<td>100</td>
<td>61</td>
<td>24*</td>
<td>19*</td>
</tr>
<tr>
<td>mean1</td>
<td>2210</td>
<td>2224</td>
<td>876</td>
<td>688</td>
</tr>
<tr>
<td>percent</td>
<td>100</td>
<td>101</td>
<td>40</td>
<td>31</td>
</tr>
</tbody>
</table>

# animal number U/L cholinesterase activity units/liter
* statistically significant p< 0.05
1. Mean calculated omitting control animal # B43793

Animal # B43793 is clearly a high value outlier, over 3 times higher than the next highest value (2920). Omitting this outlier removes the difference between control and 1 ppm while the depressed activity is clearly present at 50 and 100 ppm.

In females at 1 ppm hippocampus cholinesterase was significantly depressed at 14 weeks (78%). Terminal olfactroy bulb cholinesterase activity was also 78% of control but the difference was not statistically significant. Individual animal values for olfactory bulb were as follows;
<table>
<thead>
<tr>
<th>Animal</th>
<th>0 ppm U/L</th>
<th>1 ppm U/L</th>
<th>25 ppm U/L</th>
<th>50 ppm U/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>B43817</td>
<td>6460</td>
<td>4660</td>
<td>900</td>
<td>400</td>
</tr>
<tr>
<td>B43818</td>
<td>3740</td>
<td>3300</td>
<td>1760</td>
<td>400</td>
</tr>
<tr>
<td>B43818</td>
<td>6540</td>
<td>3920</td>
<td>2480</td>
<td>620</td>
</tr>
<tr>
<td>B43820</td>
<td>5180</td>
<td>4540</td>
<td>NT</td>
<td>700</td>
</tr>
<tr>
<td>B43821</td>
<td>4980</td>
<td>4540</td>
<td>2160</td>
<td>720</td>
</tr>
<tr>
<td>Mean</td>
<td>5380</td>
<td>4192</td>
<td>1825</td>
<td>568</td>
</tr>
<tr>
<td>Percent</td>
<td>100</td>
<td>78</td>
<td>34*</td>
<td>11*</td>
</tr>
</tbody>
</table>

*animal number U/L cholinesterase activity units/liter

* statistically significant p< 0.05

In this case there is no obvious outlier, with high to low ratios of 1.7, 1.4, 2.8 and 1.8 for the 0, 1, 25 and 50 ppm doses respectively. One may consider the depression real but not statistically significant.

**Neurobehavioral Assessment**

**Observations at removal from cage**

<table>
<thead>
<tr>
<th>Observation</th>
<th>Results (all doses)</th>
</tr>
</thead>
<tbody>
<tr>
<td>appearance of fur</td>
<td>normal</td>
</tr>
<tr>
<td>color of tears/deposits around eyes</td>
<td>none</td>
</tr>
<tr>
<td>convulsions/tremors</td>
<td>none</td>
</tr>
<tr>
<td>ease of handling/body tone</td>
<td>normal</td>
</tr>
<tr>
<td>ease of removal from cage</td>
<td>normal</td>
</tr>
<tr>
<td>excessive vocalizations</td>
<td>none</td>
</tr>
<tr>
<td>exophthalmus</td>
<td>none</td>
</tr>
<tr>
<td>lacrimation</td>
<td>none</td>
</tr>
<tr>
<td>other signs</td>
<td>none</td>
</tr>
<tr>
<td>palpebral closure</td>
<td>normal</td>
</tr>
<tr>
<td>piloerection</td>
<td>none</td>
</tr>
<tr>
<td>respiration</td>
<td>normal</td>
</tr>
<tr>
<td>salivation</td>
<td>none</td>
</tr>
<tr>
<td>writhing</td>
<td>none</td>
</tr>
</tbody>
</table>

After home cage observations, each animal was placed into a Plexiglas arena (66L X 48W X 30.5 H cm) on a flat surface covered with a clean absorbent paper for a 1-minute period to evaluate the following parameters:

<table>
<thead>
<tr>
<th>Observation</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>arousal</td>
<td>normal</td>
</tr>
<tr>
<td>circling</td>
<td>none</td>
</tr>
<tr>
<td>convulsions</td>
<td>none</td>
</tr>
<tr>
<td>diarrhea</td>
<td>none</td>
</tr>
<tr>
<td>gait</td>
<td>normal</td>
</tr>
<tr>
<td>latency to first step</td>
<td>no dose-related differences</td>
</tr>
<tr>
<td>number fecal boli</td>
<td>no differences</td>
</tr>
</tbody>
</table>

//
number rears
number urine pools
other signs
polyurea
posture
stereotypy
tremor

no differences
no differences
none
none
normal
none

At 8 weeks one high dose female (50 ppm) and 2 high dose males (100 ppm) showed tremors. At 13 weeks one mid dose (25 ppm) and one high dose female (50 ppm) showed tremors.

"The following responses were evaluated in the testing arena at the end of the 1-minute period:

<table>
<thead>
<tr>
<th>Observation</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>light approach response</td>
<td>no differences</td>
</tr>
<tr>
<td>catalepsy time</td>
<td>no differences</td>
</tr>
<tr>
<td>olfactory response</td>
<td>present</td>
</tr>
<tr>
<td>other signs</td>
<td>number showing signs/number dosed</td>
</tr>
<tr>
<td></td>
<td>males</td>
</tr>
<tr>
<td>8 weeks</td>
<td></td>
</tr>
<tr>
<td>25 ppm</td>
<td>not dosed</td>
</tr>
<tr>
<td>50 ppm</td>
<td>2/10</td>
</tr>
<tr>
<td>100 ppm</td>
<td>5/10</td>
</tr>
<tr>
<td>13 weeks</td>
<td></td>
</tr>
<tr>
<td>25 ppm</td>
<td>not dosed</td>
</tr>
<tr>
<td>50 ppm</td>
<td>3/10</td>
</tr>
<tr>
<td>100 ppm</td>
<td>8/10</td>
</tr>
<tr>
<td>observations consisted mainly in a &quot;subjective&quot; observation of slow and/or partial pupillary constriction usually in both eyes.</td>
<td></td>
</tr>
<tr>
<td>pupil response</td>
<td>present</td>
</tr>
<tr>
<td>righting reflex</td>
<td>At 13 weeks 4 females at the high dose (50 ppm) showed mildly abnormal righting response</td>
</tr>
<tr>
<td>touch reflex</td>
<td>no differences</td>
</tr>
</tbody>
</table>

"The following parameters were evaluated at the same intervals as the FOB testing:

<table>
<thead>
<tr>
<th>Observation</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>forelimb grip strength</td>
<td>Statistically significant decrease (p&lt;0.5) in the high dose females (50 ppm) at 4, 8 and 13 weeks. A dose-response relationship not apparent in the lower doses.</td>
</tr>
</tbody>
</table>
hindlimb grip strength

Statistically significant decrease (p< 0.5) in the high dose females (50 ppm) at 4, 8 and 13 weeks. A dose-response relationship not apparent in the lower doses.

Statistically significant decrease (p< 0.5) in the high dose males (100 ppm) at 4 and 13 weeks. A dose-response relationship not apparent in the lower doses.

landing foot splay
rectal body temperature
tail flick latency

no differences
no differences
no differences

Auditory Startle Response

No evidence of a treatment related effect was observed in the auditory startle response. However, in many cases the Standard Deviation was equal to or larger than the mean indicating a large degree of individual animal variation. Individual animal data confirm this. The first page of Appendix 7 from the report (Appendix IV, page 372) presents the individual male and female control data. Individual animal variation is readily apparent and appears to be without any pattern or consistancy within the single animal derived numbers. The same observation can be made for the treated groups. It must be concluded that normal variation in the tested parameters is so large as to make it impossible to detect effects less than comatose or dead animals.

Locomotor Activity Counts

No evidence of a treatment related effect was observed in the locomotor activity counts. A single block, high dose males, 11-15 minutes, week 4 was significantly decreased from the concurrent control value. This value is considered an anomaly and of no toxicological significance. Individual animal data show a large variation in activity in this period. Some animals are essentially inactive but subsequently 'come back to life'. Even in the control groups, individual animal activity is extremely variable with only a general pattern of the animals being more active at the beginning of the test and decreasing in activity with time. It must be concluded that the test is not sensitive to small changes in activity.

Gross necropsy

No abnormalities were observed at gross necropsy.
Histopathology

No evidence of treatment related abnormalities were observed in the nervous tissue examined.

Discussion

Dose related depression of cholinesterase activity was clearly the most sensitive indication of parathion toxicity in this study showing significant depression at the respective mid and high doses for both sexes with minimal recovery. Dose related and statistically significant depression of cholinesterase activity in plasma, erythrocytes and all brain sections in both sexes at their respective intermediate and high doses (males 50 and 100 ppm and females 25 and 50 ppm). In the 1 ppm males erythrocyte cholinesterase activity was statistically significantly depressed at 8 and 14 weeks, 86 and 85 percent of controls respectively. In the 1 ppm females hippocampus activity was statistically significantly depressed 14 weeks (78 percent of control). In the high dose recovery animals at 17 weeks, plasma and cerebellum cholinesterase activity had recovered. Erythrocyte and the remaining brain area activity had recovered to some extent but the remaining depression was statistically significant.

Body weight and weight gains were depressed in the respective high doses in males and females.

Very few of the parameters in the functional observational battery gave any indication of a treatment related effect. The only clearly observed effects were fore and hindlimb grip strength at the respective high doses in both sexes.

At 8 weeks one high dose female (50ppm) and 2 high dose males (100 ppm) showed tremors. At 13 weeks one mid dose (25 ppm) and one high dose female (50 ppm) showed tremors. At 8 and 13 weeks there were 'subjective' observations of slow and/or partial pupillary constriction in intermediate and high dose animals in both sexes. The number of animals showing the effect appeared to be dose related.

Forelimb grip strength showed a statistically significant decrease (p< 0.5) in the high dose females (50 ppm) at 4, 8 and 13 weeks. A dose-response relationship not apparent in the lower doses.

Hindlimb grip strength showed a statistically significant decrease (p< 0.5) in the high dose females (50 ppm) at 4, 8 and 13 weeks. A dose-response relationship not apparent in the lower doses. Statistically significant decrease (p< 0.5) in the high dose males (100 ppm) at 4 and 13 weeks. A dose-response relationship not apparent in the lower doses.
The material not included contains the following type of information:

____ Identity of product inert ingredients.

____ Identity of product impurities.

____ Description of the product manufacturing process.

____ Description of quality control procedures.

____ Identity of the source of product ingredients.

____ Sales or other commercial/financial information.

____ A draft product label.

____ The product confidential statement of formula.

____ Information about a pending registration action.

____ FIFRA registration data.

____ The document is a duplicate of page(s) ________.

____ The document is not responsive to the request.

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.